Nimodipine

Nimodipine, sold under the brand name Nimotop among others, is calcium channel blocker used in preventing vasospasm secondary to subarachnoid hemorrhage (a form of cerebral hemorrhage). It was originally developed within the calcium channel blocker class as it was used for the treatment of high blood pressure, but is not used for this indication.

Nimodipine
Clinical data
Trade namesNimotop, Nymalize, others
AHFS/Drugs.comMonograph
MedlinePlusa689010
License data
Pregnancy
category
  • AU: C
Routes of
administration		Intravenous, by mouth
Drug classDihydropyridine calcium channel blocker
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability13% (by mouth)
Protein binding95%
MetabolismHepatic
Elimination half-life8–9 hours
ExcretionFeces and Urine
Identifiers
  • 3-(2-Methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.060.096
Chemical and physical data
FormulaC21H26N2O7
Molar mass418.446 g·mol−1
3D model (JSmol)
Melting point125 °C (257 °F)
  • O=C(OC(C)C)\C1=C(\N/C(=C(/C(=O)OCCOC)C1c2cccc([N+]([O-])=O)c2)C)C
  • InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3 Y
  • Key:UIAGMCDKSXEBJQ-UHFFFAOYSA-N Y
  (verify)

It was patented in 1971 and approved for medical use in the US in 1988. It was approved for medical use in Germany in 1985.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.